Disease × agent evidence record

Igpro20 for Long COVID: evidence, trials and status

Trials of Igpro20 in Long COVID are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest.

1 registered trials 0 recruiting 23 publications Evidence tier B · Moderate Score 36.5
Research Tracker › Pairs › Long COVID › Igpro20
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Igpro20 is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Igpro20 to Long COVID: 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT06524739, sponsored by CSL Behring). It plans or enrolled 16 participants. Registered activity dates to 2024. The literature layer holds 23 publications for this pair: 1 clinical trial publication and 22 other publications. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.

Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.

Open in Repurposing ExplorerAgent page: Igpro20Long COVID hubLong COVID biomarkers & interventionsPubChem

Evidence table

Evidence tierB · Moderate
Evidence score36.5 (trials 2.5, literature 24.0, tier 10, approved bonus 0.0)
Registered trials1 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 1 other
Linked publications23 (22 other publications, 1 clinical trial publication)
Agent typeDevice (Medical Device)
Development stage (any indication)Investigational
Mechanism / classNeurological / Autonomic
Data sourcesOSMF therapeutic agent database, ClinicalTrials.gov, PubMed
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT06524739Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
CSL Behring · 2024
terminatedPhase 316

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

Recorded mechanism or class: Neurological / Autonomic.

Clinical notes: Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.

Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.

Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.

Frequently asked questions

Is Igpro20 approved for Long COVID?

Igpro20 is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Igpro20 in clinical trials for Long COVID?

ClinicalTrials.gov lists 1 registered trial linking Igpro20 to Long COVID: 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT06524739, sponsored by CSL Behring). It plans or enrolled 16 participants. Registered activity dates to 2024.

What does the evidence show for Igpro20 in Long COVID?

Trials of Igpro20 in Long COVID are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is B (Moderate), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.

Cite this page

Open Source Medicine Foundation. Igpro20 for Long COVID: evidence, trials and status. OSMF Research Tracker. Updated 2026-10-07. https://research.opensourcemed.info/pairs/long-covid/igpro20.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.